Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
189.4 GBX | +0.21% | +0.96% | -8.72% |
03-28 | Aviva and L&G cut; mixed calls on Diploma | AN |
03-13 | Advanced Medical 2023 profit falls; buys Peters Surgical | AN |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 24.35 times its estimated earnings per share for the ongoing year.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.72% | 516M | C+ | ||
+9.64% | 27.27B | B+ | ||
-29.83% | 3.12B | B- | ||
-15.97% | 2.53B | C+ | ||
+18.11% | 2.47B | - | A- | |
+3.70% | 2B | B | ||
-9.47% | 1.91B | - | ||
-2.22% | 1.48B | B | ||
+2.53% | 1.3B | - | ||
+18.92% | 1.18B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AMS Stock
- Ratings Advanced Medical Solutions Group plc